Calgary, Alberta - TheNewswire - January 10, 2022 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV:OTC) is pleased to provide an update on the status of preclinical studies for its first product, the Bionic Lens.  

The preclinical studies for the Bionic Lens, consisting of the lens retainer and the lens itself, commenced on October 22, 2021.  The preclinical studies are planned in three stages:

“Our research team has planned three stages of preclinical studies to test the two components of the Bionic Lens technology - the retainer and the optic element,” said Dr. Mark Lee, President & CEO of Ocumetics. “Each of these components is considered a stand-alone medical device, which will be tested separately to meet regulatory approval requirements.”

“We are pleased with the learnings obtained from the first stage of our preclinical studies,” adds Dr. Lee.  “We obtained invaluable data from our Stage 1 work that we used to refine the design of the Bionic Lens technology to 1) enhance the functioning of the lens in the eye and 2) to streamline the Bionic Lens surgical procedure.”

Successful preclinical studies will be followed by Phase 1 human clinical trials, starting with a planned Proof-of-Concept study in the Fall of 2022.

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry - the Bionic Lens.  The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.